Skip to main content

Nano-Vaccine Effective

Needle-Free: New Nano-Vaccine Effective Against All COVID-19 Variants


A new nano-vaccine developed by TAU and the University of Lisbon offers a needle-free, room-temperature-storable solution against COVID-19, targeting all key variants effectively.

Professor Ronit Satchi-Fainaro’s lab at Tel Aviv University’s Faculty of Medical and Health Sciences has collaborated with Professor Helena Florindo’s lab at the University of Lisbon to develop a novel nano-vaccine for COVID-19. This nano-vaccine, a 200-nanometer particle, effectively trains the immune system against all common COVID-19 variants, performing as well as existing vaccines.

Unlike other vaccines, it is conveniently administered as a nasal spray and does not require a cold supply chain or ultra-cold storage. These distinctive features pave the way for vaccinating populations in developing countries and the future development of simpler, more effective, and less expensive vaccines. The groundbreaking study was featured on the cover of the prestigious journal Advanced Science.

Development and Design of the Nano-Vaccine

Prof. Satchi-Fainaro explains: “The new nano-vaccine’s development was inspired by a decade of research on cancer vaccines. When the COVID-19 pandemic began, we set a new goal: training our cancer platform to identify and target the coronavirus. Unlike Moderna and Pfizer, we did not rely on full protein expression via mRNA. Instead, using our computational bioinformatics tools, we identified two short and simple amino acid sequences in the virus’s protein, then synthesized them, and encapsulated them in nanoparticles.” Eventually, this nano-vaccine proved effective against all major variants of COVID-19, including Beta, Delta, Omicron, etc.

Benefits of the Nano-Vaccine: Needle-Free Administration

“Our nano-vaccine offers a significant advantage over existing vaccines because it is needle-free and administered as a nasal spray,” notes Prof. Satchi-Fainaro. “This eliminates the need for skilled personnel such as nurses and technicians to administer injections, while also reducing risks of contamination and sharp waste. Anyone can use a nasal spray, with no prior training.”

Advantages in Storage and Shipping

Another major advantage of the revolutionary nano-vaccine is its minimal storage requirements. Moderna’s sensitive mRNA-based vaccine must be kept at -20°C and Pfizer’s at -70°C, generating great logistic and technological challenges, such as shipping in special aircraft and ultra-cold storage – from the factory to the vaccination station.

Prof. Satchi-Fainaro’s novel synthetic nanoparticles are far more durable and can be stored as a powder at room temperature. “There’s no need for freezing or special handling,” she says. “You just mix the powder with saline to create the spray. For testing purposes (as part of the EU’s ISIDORe (Integrated Services for Infectious Disease Outbreak Research) feasibility program) we shipped the powder at room temperature to the INSERM infectious diseases lab in France. Their tests showed that our nano-vaccine is at least as effective as Pfizer’s vaccine.”

Future Implications and Expanding Applications

These important advantages—ease of nasal administration and regular storage and shipping — pave the way towards vaccinating at-risk populations in low-income countries and remote regions, which existing vaccines are unable to reach. Moreover, the novel platform opens the door for quickly synthesizing even more effective and affordable vaccines for future pandemics. “This is a plug-and-play technology,” explains Prof. Satchi-Fainaro. “It can train the immune system to fight cancer or infectious diseases like COVID-19. We are currently expanding its use to target a range of additional diseases, enabling the rapid development of relevant new vaccines when needed.”

COVID-19 variants, SARS-CoV-2, Omicron, Delta variant, Alpha variant, Beta variant, Gamma variant, Lambda variant, Mu variant, XBB, BA.2, BA.5, EG.5, pandemic, coronavirus mutations, spike protein, viral transmission, vaccine efficacy, immune escape, public health, antiviral treatments, genome sequencing, global surveillance, variant of concern, outbreak response, epidemiology,

#COVID19Variants, #SARSCoV2, #Omicron, #DeltaVariant, #AlphaVariant, #BetaVariant, #GammaVariant, #LambdaVariant, #MuVariant, #XBB, #BA2, #BA5, #EG5, #Pandemic, #CoronavirusMutations, #SpikeProtein, #VaccineEfficacy, #ImmuneEscape, #PublicHealth, #AntiviralTreatments, #GenomeSequencing, #GlobalSurveillance, #VariantOfConcern, #OutbreakResponse, #Epidemiology

Comments

Popular posts from this blog

Fruitful innovation

Fruitful innovation: Transforming watermelon genetics with advanced base editors The development of new adenine base editors (ABE) and adenine-to-thymine/ guanine base editors (AKBE) is transforming watermelon genetic engineering. These innovative tools enable precise A:T-to-G and A:T-to-T base substitutions, allowing for targeted genetic modifications. The research highlights the efficiency of these editors in generating specific mutations, such as a flowerless phenotype in ClFT (Y84H) mutant plants. This advancement not only enhances the understanding of gene function but also significantly improves molecular breeding, paving the way for more efficient watermelon crop improvement. Traditional breeding methods for watermelon often face challenges in achieving desired genetic traits efficiently and accurately. While CRISPR/Cas9 has provided a powerful tool for genome editing, its precision and scope are sometimes limited. These limitations highlight the need for more advanced gene-e...

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...

Genetics study on COVID-19

Large genetic study on severe COVID-19 Bonn researchers confirm three other genes for increased risk in addition to the known TLR7 gene Whether or not a person becomes seriously ill with COVID-19 depends, among other things, on genetic factors. With this in mind, researchers from the University Hospital Bonn (UKB) and the University of Bonn, in cooperation with other research teams from Germany, the Netherlands, Spain and Italy, investigated a particularly large group of affected individuals. They confirmed the central and already known role of the TLR7 gene in severe courses of the disease in men, but were also able to find evidence for a contribution of the gene in women. In addition, they were able to show that genetic changes in three other genes of the innate immune system contribute to severe COVID-19. The results have now been published in the journal " Human Genetics and Genomics Advances ". Even though the number of severe cases following infection with the SARS-CoV-...